Last reviewed · How we verify
NCT03613259
Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma
EARLY_PHASE1 trial testing Fluorothymidine F-18 in Stage II Adult Soft Tissue Sarcoma. Withdrawn.
1 June 2022
Quick facts
| Lead sponsor | OHSU Knight Cancer Institute |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Start date | 1 June 2020 |
| Primary completion | 1 June 2022 |
| Estimated completion | 1 June 2022 |
Drugs / interventions tested
- Fluorothymidine F-18
- Laboratory Biomarker Analysis — full drug profile →
- Positron Emission Tomography
Conditions studied
- Stage II Adult Soft Tissue Sarcoma — all drugs for Stage II Adult Soft Tissue Sarcoma →
- Stage IIA Adult Soft Tissue Sarcoma — all drugs for Stage IIA Adult Soft Tissue Sarcoma →
- Stage IIB Adult Soft Tissue Sarcoma — all drugs for Stage IIB Adult Soft Tissue Sarcoma →
- Stage IIC Adult Soft Tissue Sarcoma — all drugs for Stage IIC Adult Soft Tissue Sarcoma →
Sponsor
OHSU Knight Cancer Institute
Who can join
18 and older, any sex, with Stage II Adult Soft Tissue Sarcoma or Stage IIA Adult Soft Tissue Sarcoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This pilot early phase I trial studies how well fluorothymidine F-18 positron emission tomography (PET) works in imaging patients with intermediate or high grade soft tissue sarcoma. Fluorothymidine F-18 PET may provide useful information about the tumor's response to treatment and may give the doctors early results that would better help to plan the post-surgical therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03613259
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fluorothymidine F-18
Trials testing the same drug.
- NCT04221438 — Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement · Phase 2 · terminated
- NCT03422731 — Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute · EARLY_PHASE1 · recruiting
- NCT02392429 — FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia · Phase 2 · active not recruiting
- NCT01251874 — Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer · Phase 1 · active not recruiting
- NCT00880074 — FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies · Phase 1 · completed
Other OHSU Knight Cancer Institute trials
Trials by the same sponsor.
- NCT05453851 — A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatme · Phase 1, PHASE2 · not yet recruiting
- NCT07511504 — Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanc · Phase 2 · not yet recruiting
- NCT07434128 — Mammogram Pretreatment With Ulipristal Acetate · Phase 2 · not yet recruiting
- NCT07504835 — GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer · NA · not yet recruiting
- NCT07498517 — Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03613259 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by OHSU Knight Cancer Institute
- Last refreshed: 9 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03613259.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing